(Q46846107)

25 December 2017

title

Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma (English)

1 reference

25 December 2017

1 reference

1 reference

1 reference

Faye M Johnson

1

1 reference

25 December 2017

Lee M Krug

2

1 reference

25 December 2017

Hai T Tran

3

1 reference

25 December 2017

Stephanie Shoaf

4

1 reference

25 December 2017

Victor G Prieto

5

1 reference

25 December 2017

Pheroze Tamboli

6

1 reference

25 December 2017

Beverly Peeples

7

1 reference

25 December 2017

Jyoti Patel

8

1 reference

25 December 2017

Bonnie S Glisson

9

1 reference

25 December 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

25 December 2017

published in

Cancer

1 reference

25 December 2017

volume

106

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

366-374

1 reference

25 December 2017

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Chemotherapy as treatment of primary and recurrent small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Analysis of protein tyrosine kinase expression in melanocytic lesions by tissue array

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Cisplatin-induced platelet activation requires mononuclear cells: role of GMP-140 and modulation of procoagulant activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Potential involvement of the cyclooxygenase-2 pathway in the regulation of tumor-associated angiogenesis and growth in pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

In vivo efficacy of STI571 in xenografted human small cell lung cancer alone or combined with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21640

7 January 2021

Identifiers

DOI

10.1002/CNCR.21640

1 reference

25 December 2017

1 reference

25 December 2017